News

Wildlife conservation activists have welcomed an update to China’s list of officially sanctioned medicines, which drops 13 traditional formulas containing pangolin parts. The move offers the world’s most trafficked mammal a better shot at survival and has raised cautious optimism among conservationists.

On a cold, wet night in eastern Malaysia, conservation biologist Elisa Panjang trekked through a nature reserve in search of pangolins—the only scaled mammal in the world. If she had found one that evening in 2017, she would have fitted the animal with a tracking device and studied how it interacted with the nearby palm tree plantations encroaching on pangolin habitat.

The Chinese Pharmacopoeia is the legal technical standard which should be followed during the research, production, use, and administration of drugs. At present, the new edition of the Chinese Pharmacopoeia is planned to be promulgated and implemented. This article summarizes and analyzes the main characteristics and the content of updates and amendments of the Chinese Pharmacopoeia 2025 Edition (Volume I), to provide a reference for the correct understanding and accurate implementation the new edition of the pharmacopoeia.

In accordance with relevant work arrangements and the requirements outlined in the Compilation Outline for the 2025 Edition of the Chinese Pharmacopoeia, the National Pharmacopoeia Commission proposes that the following 19 varieties will no longer be included in Part I of the 2025 Edition of the Chinese Pharmacopoeia.

In order to effectively strengthen the protection and management of pangolins and fulfill the obligations under the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), and in accordance with the Wildlife Protection Law and other relevant regulations, the following requirements are hereby notified

People’s Daily Online, Beijing, October 22 (Reporter Sun Hongli) The National Medical Products Administration (NMPA) and the National Administration of Traditional Chinese Medicine (NATCM) recently jointly issued the “Announcement on Matters Concerning Supporting the Research and Development of Substitutes for Rare and Endangered Chinese Medicinal Materials” (hereinafter referred to as the “Announcement”)